The Certara Blog

Author: Mark Hovde

Mark Hovde is the Senior Vice President of Strategy and Corporate Development at Certara. He brings more than 20 years of product development, marketing, sales, and general management leadership to his work with Certara’s customers and partners. Prior to his current role, Hovde held a number of leadership positions in several innovative technology companies, including Entelos and Fast Track Systems (now Medidata Solutions). Prior to entering the R&D technology and services industry, he held leadership positions in commercial banking and management consulting. Hovde is an author and speaker on issues facing R&D management. He serves on the finance committee of the Association of Clinical Pharmacology and Therapeutics. He holds a B.S. in economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.

Recent Posts

What is Model-based Drug Development Worth?

If you have ever argued, as we have, for the resources and time needed for model-based drug development (MBDD), you have likely encountered that irritating accountant in the room who says, “Sure, this modeling stuff sounds interesting, but how much MONEY will this save us?” My answer: $97M of savings per New Drug Application (NDA). […]

Read More

Is the Maturation of Quantitative Systems Pharmacology a Moonshot?

At Certara, we are not afraid to think big. In fact, solving the hardest problems in pharmaceutical R&D is our passion. You might say that some of our ambitions could be described as “moonshots.” After all, they meet the criteria put forth by the Google X moonshot program. We seek to address the huge problem […]

Read More

Seeing the Strategic Value of Biosimulation Technology

They say beauty is in the eye of the beholder. One could also say that the benefits of biosimulation are in the eye of the beholder. How does the beholder, in this case, a drug developer, see the benefits of these approaches? All reputable businesses use “generally accepted accounting principles” to manage, measure, and communicate […]

Read More

7 Horrible Mistakes You’re Making with Your Drug Development Strategy

In thinking about the complex nature of drug development, I’m often reminded of a Dwight Eisenhower quote: “In preparing for battle, I’ve always found that plans are useless, but planning is essential,” Drug development is a risky business. According to a 2014 study from the Tufts Center for the Study of Drug Development, “the estimated […]

Read More
Learn More LinkedIn Twitter Facebook Email